Skip to content
Markets News
Stocks1 min read

TCW Letter Highlights BioMarin’s Valuation Measures

Makkler Newsroom
October 1, 2026

The mid-cap fund listed BioMarin as a 2.55% holding and said it met three valuation characteristics when the fund initiated its position.

BioMarin Pharmaceutical was among the companies highlighted in TCW Relative Value Mid Cap Fund’s second-quarter 2026 investor letter. The letter listed the biotechnology company as a 2.55% holding.

TCW said BioMarin met three of five valuation characteristics when the fund initiated its position during the quarter. Those measures were price-to-earnings, price-to-cash-flow and price-to-book.

The fund described BioMarin as focused on developing and commercializing medicines for people with rare, genetically defined diseases. Its portfolio includes enzyme replacement therapies and small-molecule drugs, according to the letter.

BioMarin shares closed at $60 on September 30, giving the company a market capitalization of $11.61 billion, according to the article. The stock’s reported 52-week range was $49.26 to $170.98.

Topics
BMRNTCW Relative Value Mid Cap Fund
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.